Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer.

Mast JM, Kuppusamy P.

Front Oncol. 2018 Nov 20;8:527. doi: 10.3389/fonc.2018.00527. eCollection 2018.

2.
3.

Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.

Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J.

Mol Cancer. 2014 Sep 8;13:207. doi: 10.1186/1476-4598-13-207.

4.

Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.

Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.

Mol Pharm. 2015 Apr 6;12(4):1105-20. doi: 10.1021/mp5008629. Epub 2015 Mar 2.

PMID:
25661724
5.

Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.

Speyer CL, Bukhsh MA, Jafry WS, Sexton RE, Bandyopadhyay S, Gorski DH.

Breast Cancer Res Treat. 2017 Nov;166(2):407-419. doi: 10.1007/s10549-017-4435-x. Epub 2017 Aug 5.

PMID:
28780701
6.

Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.

Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q, Dong X, Liu F, Wang Y, Yao N, Cheng S, Li L, Sun S.

Cancer Biol Ther. 2017 Apr 3;18(4):205-213. doi: 10.1080/15384047.2017.1294288. Epub 2017 Feb 21.

7.

Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.

Camirand A, Fadhil I, Luco AL, Ochietti B, Kremer RB.

Am J Cancer Res. 2013 Nov 1;3(5):500-8. eCollection 2013.

8.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD.

Clin Cancer Res. 2013 Nov 15;19(22):6163-72. doi: 10.1158/1078-0432.CCR-12-3826. Epub 2013 Sep 9.

9.

Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.

Yehia L, Boulos F, Jabbour M, Mahfoud Z, Fakhruddin N, El-Sabban M.

PLoS One. 2015 Jun 5;10(6):e0129356. doi: 10.1371/journal.pone.0129356. eCollection 2015.

10.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

11.

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.

Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052.

12.

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.

BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.

13.

Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy.

Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D, Jain RK.

Cancer Res. 2000 Aug 15;60(16):4556-60. Erratum in: Cancer Res 2001 Aug 15;61(16):6304.

14.

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.

Vacas E, Muñoz-Moreno L, Valenzuela PL, Prieto JC, Schally AV, Carmena MJ, Bajo AM.

Peptides. 2016 Dec;86:153-161. doi: 10.1016/j.peptides.2016.11.004. Epub 2016 Nov 2.

PMID:
27816751
15.

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.

Martin JL, Julovi SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC.

Breast Cancer Res. 2017 Aug 4;19(1):90. doi: 10.1186/s13058-017-0882-x.

16.

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.

Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38. doi: 10.1073/pnas.1421438111. Epub 2014 Dec 1.

17.

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS.

Cell Cycle. 2014;13(20):3191-201. doi: 10.4161/15384101.2014.950126.

18.

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.

Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.

BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-017-3283-8.

19.

Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.

Zagon IS, Porterfield NK, McLaughlin PJ.

Exp Biol Med (Maywood). 2013 Jun;238(6):589-99. doi: 10.1177/1535370213489492.

PMID:
23918871
20.

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

Simon N, Antignani A, Sarnovsky R, Hewitt SM, FitzGerald D.

J Natl Cancer Inst. 2016 Apr 13;108(8). doi: 10.1093/jnci/djw028. Print 2016 Aug.

Supplemental Content

Support Center